AMLX vs. NVCT, FGEN, SYRS, SGMT, PDSB, DMAC, RPTX, KPTI, VTGN, and ACET
Should you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Nuvectis Pharma (NVCT), FibroGen (FGEN), Syros Pharmaceuticals (SYRS), Sagimet Biosciences (SGMT), PDS Biotechnology (PDSB), DiaMedica Therapeutics (DMAC), Repare Therapeutics (RPTX), Karyopharm Therapeutics (KPTI), Vistagen Therapeutics (VTGN), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Nuvectis Pharma (NASDAQ:NVCT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
Nuvectis Pharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.68, suggesting that its stock price is 168% less volatile than the S&P 500.
Amylyx Pharmaceuticals received 17 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 88.89% of users gave Nuvectis Pharma an outperform vote while only 64.10% of users gave Amylyx Pharmaceuticals an outperform vote.
Nuvectis Pharma has a net margin of 0.00% compared to Nuvectis Pharma's net margin of -17.86%. Nuvectis Pharma's return on equity of 3.92% beat Amylyx Pharmaceuticals' return on equity.
96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 38.8% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Nuvectis Pharma had 5 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 20 mentions for Nuvectis Pharma and 15 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.05 beat Nuvectis Pharma's score of 0.43 indicating that Nuvectis Pharma is being referred to more favorably in the media.
Amylyx Pharmaceuticals has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Nuvectis Pharma presently has a consensus target price of $21.00, suggesting a potential upside of 228.13%. Amylyx Pharmaceuticals has a consensus target price of $32.67, suggesting a potential upside of 1,761.35%. Given Nuvectis Pharma's higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Nuvectis Pharma.
Summary
Amylyx Pharmaceuticals beats Nuvectis Pharma on 9 of the 17 factors compared between the two stocks.
Get Amylyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amylyx Pharmaceuticals Competitors List
Related Companies and Tools
